Fåhraeus Startup & Growth FSG Fund II invests €3 million in Finnish biotech firm Aplagon Oy to support the development of its innovative APAC therapy for thrombo-inflammatory diseases.

Target Company: Aplagon Oy

Aplagon Oy, located in Helsinki, Finland, is a pioneering clinical-stage biopharmaceutical firm focusing on the development of innovative therapies for thrombo-inflammatory diseases. Its flagship therapeutic candidate, APAC, represents a significant advancement in medical treatment by integrating antiplatelet, anticoagulant, and anti-inflammatory properties. This combination seeks to meet critical unmet medical needs in severe cardiovascular conditions, positioning Aplagon as a key player in its field.

Developing such therapies is essential in addressing serious health challenges, particularly for patients suffering from conditions that result in high morbidity and mortality. Aplagon's efforts aim to revolutionize treatment methods and improve patient outcomes, significantly enhancing the quality of life for individuals afflicted by these debilitating ailments.

Industry Overview in Finland

Finland's biotechnology sector has witnessed remarkable growth over the past decade, driven by substantial investments in research and development. The Nordic country boasts a robust ecosystem, comprising universi